Results of IT and radiation therapy
| Date . | WBC count, ×109/L . | RBC count, ×109/L . | Flow cytometry . | Treatment . |
|---|---|---|---|---|
| 11 August 2017 | 678 | 153 | (+) | Ara-C 100 mg |
| 16 August 2017 | 303 | 96 | (+) | Ara-C 100 mg , hydrocortisone 50 mg |
| 18 August 2017 | 472 | 87 | (+) | Ara-C 100 mg , hydrocortisone 50 mg1-4,12,15-17 |
| 22 August 2017 | 565 | 67 | (+) | Methotrexate 15 mg, ara-C 40 mg, hydrocortisone 50 mg |
| 25 August 2017 | 97 | 27 | (+) | Methotrexate 15 mg, ara-C 40 mg, hydrocortisone 50 mg |
| 28 August 2017 | 122 | 46 | (+) | Methotrexate 15 mg, ara-C 40 mg, hydrocortisone 50 mg |
| 31 August 2017 | 149 | 39 | (+) | Methotrexate 15 mg, ara-C 40 mg, hydrocortisone 50 mg → whole brain radiation 11-27 September 2017 |
| 1 December 2017 | 3 | 3 | (+) | Methotrexate 15 mg, ara-C 40 mg, hydrocortisone 50 mg |
| 11 December 2017 | 1 | 6 | (+) | Alemtuzumab 1 mg and hydrocortisone 50 mg |
| 15 December 2017 | 2 | 1550 | (−) | Alemtuzumab 3 mg and hydrocortisone 50 mg |
| 18 December 2017 | 0 | 61 | (−) | Alemtuzumab 3 mg and hydrocortisone 50 mg |
| 22 December 2017 | 0 | 87 | (−) | Alemtuzumab 3 mg and hydrocortisone 50 mg |
| 26 December 2017 | 0 | 816 | (−) | Alemtuzumab 3 mg and hydrocortisone 50 mg |
| 29 December 2017 | 2 | 3 | (−) | Alemtuzumab 3 mg and hydrocortisone 50 mg |
| 5 January 2018 | 0 | 665 | (−) | Alemtuzumab 3 mg and hydrocortisone 50 mg |
| 12 January 2018 | 0 | 7 | (−) | Alemtuzumab 3 mg and hydrocortisone 50 mg |
| 19 January 2018 | 0 | 1 | (−) | Alemtuzumab 3 mg and hydrocortisone 50 mg |
| 11 July 2018 | 0 | 1 | (−) | Evaluation only |
| Date . | WBC count, ×109/L . | RBC count, ×109/L . | Flow cytometry . | Treatment . |
|---|---|---|---|---|
| 11 August 2017 | 678 | 153 | (+) | Ara-C 100 mg |
| 16 August 2017 | 303 | 96 | (+) | Ara-C 100 mg , hydrocortisone 50 mg |
| 18 August 2017 | 472 | 87 | (+) | Ara-C 100 mg , hydrocortisone 50 mg1-4,12,15-17 |
| 22 August 2017 | 565 | 67 | (+) | Methotrexate 15 mg, ara-C 40 mg, hydrocortisone 50 mg |
| 25 August 2017 | 97 | 27 | (+) | Methotrexate 15 mg, ara-C 40 mg, hydrocortisone 50 mg |
| 28 August 2017 | 122 | 46 | (+) | Methotrexate 15 mg, ara-C 40 mg, hydrocortisone 50 mg |
| 31 August 2017 | 149 | 39 | (+) | Methotrexate 15 mg, ara-C 40 mg, hydrocortisone 50 mg → whole brain radiation 11-27 September 2017 |
| 1 December 2017 | 3 | 3 | (+) | Methotrexate 15 mg, ara-C 40 mg, hydrocortisone 50 mg |
| 11 December 2017 | 1 | 6 | (+) | Alemtuzumab 1 mg and hydrocortisone 50 mg |
| 15 December 2017 | 2 | 1550 | (−) | Alemtuzumab 3 mg and hydrocortisone 50 mg |
| 18 December 2017 | 0 | 61 | (−) | Alemtuzumab 3 mg and hydrocortisone 50 mg |
| 22 December 2017 | 0 | 87 | (−) | Alemtuzumab 3 mg and hydrocortisone 50 mg |
| 26 December 2017 | 0 | 816 | (−) | Alemtuzumab 3 mg and hydrocortisone 50 mg |
| 29 December 2017 | 2 | 3 | (−) | Alemtuzumab 3 mg and hydrocortisone 50 mg |
| 5 January 2018 | 0 | 665 | (−) | Alemtuzumab 3 mg and hydrocortisone 50 mg |
| 12 January 2018 | 0 | 7 | (−) | Alemtuzumab 3 mg and hydrocortisone 50 mg |
| 19 January 2018 | 0 | 1 | (−) | Alemtuzumab 3 mg and hydrocortisone 50 mg |
| 11 July 2018 | 0 | 1 | (−) | Evaluation only |
RBC, red blood cell; WBC, white blood cell.